Exploring Solid-State Chemistry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Exploring Solid-State Chemistry
Optimizing the solid form of a drug reaps scientific and technical awards.


Pharmaceutical Technology
Volume 32, Issue 11, pp. 58-64


Patricia Van Arnum (GLOW IMAGES/GETTY IMAGES)
Solid-form characterization and research are important for improving the understanding of and modifying the physical properties of active pharmaceutical ingredients (APIs) to ensure therapeutic benefit, optimize product development, and protect intellectual property. Early in drug development, the primary goal is to find a stable form of the drug, but the potential patentability of other solid forms offers further opportunities in maintaining product exclusivity or for product extension. Solid-state chemistry is of growing importance not only for pharmaceutical companies in their drug development, but also for contract manufacturers and specialists serving the pharmaceutical industry.

Polymorphs: key considerations


GLOW IMAGES/GETTY IMAGES
Screening for and identifying polymorphs when developing and manufacturing APIs is an ongoing challenge for pharmaceutical manufacturers. Polymorphism is the ability of a compound to exist in more than one crystalline structure. Polymorphs or other solid forms are identified using a polymorph study or screen (1). Different solid forms can possess different properties, including solubility, which, in turn, can affect the bioavailability of the drug.

One of the more well-chronicled examples of polymorphism occurred in ritonavir, the API in "Norvir," a protease inhibitor developed by Abbott Laboratories (Abbott Park, IL). The drug was approved in 1996, and in mid-1998, Abbott encountered manufacturing difficulties with the capsule formulation, according to the company's 1998 annual report. Ritonavir exhibited conformational polymorphism of two unique crystal lattices that had significantly different solubility properties (2). The formation of the polymorph caused Abbott to pull the drug from the market and reformulate.

A recent analysis by SSCI, the solid-state chemistry business of Aptuit (Greenwich, CT), showed that of 245 compounds it screened, 89% had multiple solid forms. Approximately 50% of the compounds showed polymorphism, 37% were hydrates, and 31% were solvates (2). Other research conducted by Professor Ulrich Griesser at the University of Innsbruck shows a lower incidence of multiple solid forms in organic molecules: polymorphism (36%), hydrates (28%), and solvates (10%) (1, 3).

CMOs launch solid-state services

The prevalence of polymorphism and the challenge in screening and detecting them has led several contract manufacturing organizations (CMOs) to launch solid-state chemistry services. Almac Sciences (Craigavon, Northern Ireland) is the latest to do so. The company announced the launch of its solid-state chemistry business at CPhI Worldwide, which was held in Frankfurt last month. Almac's solid-state chemistry team, housed at the company's Craigavon, facility, specializes in solid-form characterization, screening and selection, and crystallization process development.

"By exploring polymorphs, salts, cocrystals, and amorphous materials, Almac can dramatically improve the characteristics of APIs," said Linda McCausland, group leader of physical sciences at Almac Sciences, in a Oct. 1, 2008 company press release. "A variety of screening methods are employed to discover new solid forms. These may provide improvement in properties such as increased solubility, bioavailability, and stability."

SAFC (St. Louis, MO), which acquired the solid-state services firm Pharmorphix in 2006, announced the second phase of a $600,000 expansion of the Pharmorphix facility in Cambridge, England, earlier this year. The company added 7500 ft2 of laboratory capacity to augment the existing 12,500-ft2 facility. The multiphase development program includes office reorganization and the installation of additional spectroscopic and diffraction equipment.

Xcelience (Tampa, FL), a provider of early drug-development services, announced in May 2008 that it added X-ray diffraction (XRD) services to its preformulation- and formulation-
development capabilities. "At the urging of several of our clients, we have committed to the purchase of an XRD instrument to enhance our overall capabilities in formulation analysis, polymorph identification, salt screen and selection, and crystallinity determination," said Mark Cappucci, team leader for preformulation and formulation of Xcelience, in a May 6, 2008 company press release.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here